Cargando…

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

OBJECTIVES: To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab. METHODS: Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visvanathan, S, van der Heijde, D, Deodhar, A, Wagner, C, Baker, D G, Han, J, Braun, J
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605572/ https://www.ncbi.nlm.nih.gov/pubmed/18495735 http://dx.doi.org/10.1136/ard.2007.084426

Ejemplares similares

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Bone and Cartilage Turnover Markers, Bone Mineral Density, and Radiographic Damage in Men with Ankylosing Spondylitis
por: Park, Min-Chan, et al.
Publicado: (2008)

Interaction effects of significant risk factors on low bone mineral density in ankylosing spondylitis
por: Sun, Wenting, et al.
Publicado: (2023)

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
por: Visvanathan, S, et al.
Publicado: (2008)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes
por: Klingberg, Eva, et al.
Publicado: (2013)

Analysis of Bone Strength and Bone Turnover Markers in Ankylosing Spondylitis with Radiological Hip Involvement
por: Liu, Wei, et al.
Publicado: (2021)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis
por: Arends, S., et al.
Publicado: (2010)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
por: Braun, Jürgen, et al.
Publicado: (2021)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

The bone mineral density of hip joint was reduced in the initial stage of ankylosing spondylitis?
por: Cai, Peng Li, et al.
Publicado: (2020)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Higher Bone Turnover Is Related to Spinal Radiographic Damage and Low Bone Mineral Density in Ankylosing Spondylitis Patients with Active Disease: A Cross-Sectional Analysis
por: Arends, Suzanne, et al.
Publicado: (2014)

Changes in bone mineral density and bone metabolic indexes in ankylosing spondylitis mouse model complicated with osteoporosis
por: Hu, Zi-Bing, et al.
Publicado: (2018)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
por: Braun, Jürgen, et al.
Publicado: (2014)

Factors relating to bone mineral density in young and middle-aged patients with ankylosing spondylitis
por: Wu, Xin, et al.
Publicado: (2021)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Bone turnover markers in serum but not in saliva correlate with bone mineral density
por: Kerschan-Schindl, Katharina, et al.
Publicado: (2020)

Bone Turnover Markers and Bone Mineral Density in Children with Hypophosphatemic Rickets
por: Michałus, Izabela, et al.
Publicado: (2022)

Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis
por: Wang, Danmin, et al.
Publicado: (2017)

The bone bridge significantly affects the decrease in bone mineral density measured with quantitative computed tomography in ankylosing spondylitis
por: Lee, So Yun, et al.
Publicado: (2021)

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
por: Arends, Suzanne, et al.
Publicado: (2020)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Association of bone mineral density with biochemical markers of bone turnover in hemodialysis children
por: Hajizadeh, Niloofar, et al.
Publicado: (2016)

3159 Bone Turnover Biomarkers May Discriminate Low Bone Mineral Density in HIV-Infected Adults
por: Collins, Lauren Frances, et al.
Publicado: (2019)

Immune mechanism of low bone mineral density caused by ankylosing spondylitis based on bioinformatics and machine learning
por: Zhang, Ding, et al.
Publicado: (2022)

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
por: Taylan, Ali, et al.
Publicado: (2012)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Evaluation of bone mineral density and bone turnover in children on anticoagulation
por: Thom, Katharina, et al.
Publicado: (2023)

Bone mineral density, bone metabolism‐related factors, and microRNA‐218 are correlated with disease activities in Chinese ankylosing spondylitis patients
por: Liu, Jiayan, et al.
Publicado: (2022)

Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men
por: El Hadidy, El Hadidy M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_15t86d2j4refs88t7h1a8oerjf